@HHorinouchi's FLAURA2 summary carries the teaching point of the day: early plasma EGFRm clearance was prognostic but not predictive, so it shouldn't be the reason to add or skip c

MeDucation· @MeDucationai · X·2026-10-22 00:50· 4 days agoScore70

Body

@HHorinouchi's FLAURA2 summary carries the teaching point of the day: early plasma EGFRm clearance was prognostic but not predictive, so it shouldn't be the reason to add or skip chemo with osimertinib. #ESMO26 #LCSM

42 views · 1 like · 0 reposts · 0 replies

Conference abstracts

2719ROmatched by Rapid oral 1: NSCLC, metastatic

FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)

https://esmocongress.esmo.org

LBA73matched by Rapid oral 1: NSCLC, metastatic

PACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line

https://esmocongress.esmo.org

引用@

🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥FLAURA2: Analysis of On-Treatment Plasma EGFRm Dynamics and Associated Clinical Outcomes in Patients (Pts) With EGFRm Advanced NSCLC Treated With First-Line (1L) Osimertinib (Osi) ± Platinum–Pemetrexed (Plat–Pem) 🎙️ @dplanchard 🔢2719RO 🎯EGFRm Clearance Prognostic but Not Predictive 🎯Osi+Plat–Pem Benefit Over Osi Alone Consistent Regardless of Clearance Status at Wk 1, 2, 3, 6; Clearance Rates Comparable Between Arms ☑️NCT04035486 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255 @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters

在 X 查看被引用的帖子

Source: MeDucation · x.com